Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor β-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Current therapeutic regimens for triple negative breast cancer (TNBC) are not very effective in majority of patients and have serious adverse effects. Tamoxifen (Tam), a selective estrogen receptor modulator (SERM), routinely used to treat estrogen receptor alpha (ERα)-positive breast cancer, has traditionally not been considered for TNBC therapy because it lacks expression of ERα, the canonical target of Tam. Challenging this conventional clinical paradigm, we have demonstrated, using genetic and pharmacological approaches, that Tam synergizes with DNA- damaging agent doxorubicin (Doxo) to increase cell death by both apoptosis and ferroptosis leading to growth inhibition of TNBC CDXs and PDXs expressing mutant p53. Mechanistically, these responses are dependent on ERβ-mutant p53 interaction enhanced by Tam, thereby disrupting p73-mutant p53 complex resulting in reactivation of p73 and transcriptomic reprogramming converging on apoptosis and ferroptosis. These studies demonstrate the potential for repurposing Tam with Doxo as an effective and safe therapeutic strategy to treat molecularly stratified TNBC.
SIGNIFICANCE
This study demonstrates synergy between Tam and Doxo in targeting a novel ERβ-mutant p53-p73 axis in TNBC to induce apoptosis, ferroptosis, and tumor regression. These results provide a mechanistic basis for repurposing Tam in combination with Doxo as an effective therapeutic strategy against TNBC, majority of which expresses mutant p53.
Article activity feed
-
Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1
-
Tamoxifen and Doxorubicin Synergistically Target Estrogen Receptor beta-Mutant p53-p73 Axis, a Therapeutically Actionable Vulnerability in Triple Negative Breast Cancer https://www.biorxiv.org/content/10.64898/2026.10.21.760572v1
-